Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Cost Calculation Method Should Be Replaced with Free Price System: PhRMA President
May 31, 2004
- Top-12 TSE-Listed Makers Report 0.1% Decline in Sales
May 31, 2004
- BUSINESS NEWS IN BRIEF
May 31, 2004
- Meet the Leaders (31)
May 31, 2004
- BULLETIN
May 31, 2004
- Japanese Healthcare Q&A (8)
May 31, 2004
- Approval of Preventive Use of Tamiflu Recommended
May 31, 2004
- Annual Business Results
May 31, 2004
- MPC's Internal Hemorrhoids Treatment Zione Recommended for Approval
May 31, 2004
- Sankyo: US Demand for Pravastatin Fuels Growth in Sales, Profits
May 31, 2004
- REGULATORY NEWS IN BRIEF
May 31, 2004
- Yamanouchi: Record Consolidated Sales of \511 Bil.
May 31, 2004
- NEW PRODUCT
May 31, 2004
- Taisho: Sales Down \1.8 Bil. Excluding Toyama's Products
May 31, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 31, 2004
- WEBSITE NEWS
May 24, 2004
- MR-kun Used by 76% of Physicians when Prescribing: So-net M3 Survey
May 24, 2004
- REGULATORY NEWS IN BRIEF
May 24, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 24, 2004
- 1st Pharmacogenomics Study Initiated in Japan on Aspirin
May 24, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…